论文部分内容阅读
日前,在北京举办的肿瘤标志物交流会上,西班牙巴塞罗那临床医院生化实验室癌症研究中心主任Rafael Molina教授就PSA的研究发展、医学价值及其对前列腺癌管理的应用进行了论述。WHO1999年发布的PSA校准方法(WHO 96/670)将截断(cut-off)值定为3.1μg/L,一般超过10μg/L考虑罹患前列腺癌的可能。但血清PSA浓度在前列腺增生和前列腺炎中均有升高,前列腺良性疾病与前列
Recently, Professor Rafael Molina, Director of the Cancer Research Center of Biochemistry Laboratory of Clinical Hospital of Barcelona, Spain, held a talk on cancer markers in Beijing. He discussed the research and development of PSA, its medical value and its application to the management of prostate cancer. The PSA calibration method published by the WHO in 1999 (WHO 96/670) has a cut-off value of 3.1 μg / L, and generally more than 10 μg / L considers the possibility of prostate cancer. However, serum PSA concentrations have increased in benign prostatic hyperplasia and prostatitis, benign prostatic diseases and the forefront